Dublin, Sept. 09, 2021 (GLOBE NEWSWIRE) -- The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering.
The "CRISPR Based Therapeutics Market, 2021-2030" report features an extensive study of the current market landscape and future opportunity for the players involved in the development of CRISPR based therapeutics for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.
One of the key objectives of the report was to estimate the future growth potential of CRISPR based therapeutics market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2021-2030.
Clinical trials of CRISPR based therapeutics are currently focused mainly on oncological and hematological disorders; however, several product candidates against certain neurological disorders and infectious diseases, specifically targeting recurrent conditions, are under investigation. Post 2014, the overall interest in this technology has grown exponentially, with several start-ups entering the market and 6 of the top 10 pharmaceutical companies restructuring their efforts in this direction.
Over time, a substantial body of evidence has also been generated validating the therapeutic applications of this technology, which has, in turn, prompted the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and has caused investors to put in significant capital into innovator companies involved in this domain, over the last two years alone.
In fact, the three leading companies in this industry segment together have combined market capitalization of more than USD 10 billion, and have raised more than USD 2.8 billion in various funding rounds. Despite the possibly limitless potential of the CRISPR/Cas technology, further investigation, probing its safety and therapeutic efficacy in large diverse populations, is required.
Key impediments to approval and other existing challenges that are being addressed by stakeholders, include off-target toxicity-related concerns and complexities related to the delivery of CRISPR components into target cells. Concerning delivery, innovators in this field have reported notable success using different types of platforms for facilitating the intracellular administration of CRISPR components; examples of successful delivery methods include electroporation, AAV vectors and lipid nanoparticles (LNPs).
A few companies are also evaluating bacteriophages as a potential delivery system for such products. Promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to push pipeline products to higher phases and on to commercialization. We believe that the market is likely to evolve at a commendable pace over the next decade.
Key Topics Covered:
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. CRISPR/Cas System
3.4. CRISPR/Cas Component Delivery Vehicles
3.5. Applications of the CRISPR/Cas System
3.6. CRISPR/Cas based Therapeutics
3.7. Challenges and Future Prospects
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. CRISPR/Cas based Therapeutics: Clinical Pipeline
4.3. CRISPR/Cas based Therapeutics: Registered Clinical Trials
4.4. CRISPR Based Therapeutics: Discovery and Preclinical Pipeline
4.5. CRISPR/Cas based Therapeutics: Developer Landscape
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. CRISPR Therapeutics
5.3. Editas Medicine
5.4. Intellia Therapeutics
5.5. Excision BioTherapeutics
5.6. Locus Biosciences
5.7. Graphite Bio
5.8. Emendo Biotherapeutics (A Subsidiary of AnGes)
5.9. Beam Therapeutics
5.10. Modalis Therapeutics
5.11. Refuge Biotechnologies
6. PATENT ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CRISPR/Cas Gene Editing Technology: Patent Analysis
6.4. CRISPR/Cas Gene Editing Technology: Patent Benchmarking
6.5. CRISPR/Cas Gene Editing Technology: Patent Valuation Analysis
6.6. Popular Patents: Analysis by Number of Citations
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. CRISPR Licensing Landscape: Surrogate Licensing
7.4. CRISPR/Cas based Therapeutics: Recent Partnerships
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding Instances
8.3. CRISPR/Cas based Therapeutics and Affiliated Technologies: Recent Funding Instances
8.4. Concluding Remarks
9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Start-ups Focused on CRISPR/Cas based Therapeutics
9.4 Benchmarking of Start-ups
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Key Assumptions and Forecast Methodology
10.4. Overall CRISPR/Cas based Therapeutics Market, 2021-2030
10.5. CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Type of Therapy
10.6. CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Therapeutic Approach
10.7. CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Therapeutic Area
10.8. CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Geographical Region
10.9. Product-wise Sales Forecast
10.9.1. EDIT-101 (Editas Medicine)
10.9.2. OTQ923 / HIX763 (Intellia Therapeutics / Novartis)
10.9.3. CTX001 for Sickle Cell (CRISPR Therapeutics)
10.9.4. CTX001 for Transfusion-Dependent Beta Thalassemia (CRISPR Therapeutics)
10.9.5. Unnamed Drug for Metastatic Gastrointestinal Epithelial Cancer (Intima Bioscience)
10.9.6. BD111 (Shanghai BD Gene Therapeutics)
10.9.7. Unnamed Drug for Beta Thalassemia Major (Shanghai Bioray Laboratories)
10.9.8. CD19-UCART (Shanghai Bioray Laboratories)
10.9.9. Unnamed Drug for Advanced Non-Small Cell Lung Cancer (Guangzhou Anjie Biomedical Technology)
10.9.10. Unnamed Drug for Advanced Prostate Cancer (Guangzhou Anjie Biomedical Technology)
11. EXECUTIVE INSIGHTS
11.1 Chapter Overview
11.2 eGenesis
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Harisson Wong (Public Relations, Burns McClellan, for eGenesis
12. CONCLUDING REMARKS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/8s4tgy
